We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+13.86%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$2.41B
AUM Growth
+$274M
Cap. Flow
+$112M
Cap. Flow %
4.66%
Top 10 Hldgs %
24.57%
Holding
158
New
13
Increased
40
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$31.6M
2
TECX
Tectonic Therapeutic
TECX
+$27.9M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$22.5M
4
PANW icon
Palo Alto Networks
PANW
+$20.8M
5
SAGE
Sage Therapeutics
SAGE
+$18.8M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$52M
2
CAFD
8point3 Energy Partners LP
CAFD
+$18.9M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$18M
4
TWLO icon
Twilio
TWLO
+$12.5M
5
SNA icon
Snap-on
SNA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 42.26%
2 Technology 16.99%
3 Consumer Discretionary 12.15%
4 Industrials 8.07%
5 Utilities 2.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$92.3M 3.83%
1,387,000
+54,460
+4% +$3.58M
XPO icon
2
XPO
XPO
$23.4B
$78.9M 3.28%
2,278,418
– –
W icon
3
Wayfair
W
$11.9B
$74.3M 3.09%
626,000
– –
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$57.9M 2.4%
370,000
+120,000
+48% +$18.8M
LOW icon
5
Lowe's Companies
LOW
$118B
$54M 2.24%
565,000
– –
COLL icon
6
Collegium Pharmaceutical
COLL
$1.17B
$52.7M 2.19%
2,207,610
– –
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.64B
$49.6M 2.06%
375,000
+149,000
+66% +$14.1M
SPLK
8
DELISTED
Splunk Inc
SPLK
$44.9M 1.86%
453,000
– –
HUBS icon
9
HubSpot
HUBS
$11.9B
$43.9M 1.82%
350,000
– –
BLUE
10
DELISTED
bluebird bio
BLUE
$43.6M 1.81%
21,431
– –
AIMT
11
DELISTED
Aimmune Therapeutics
AIMT
$43.6M 1.81%
1,620,000
+55,017
+4% +$1.68M
MIC
12
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
$43.5M 1.81%
1,032,000
– –
PANW icon
13
Palo Alto Networks
PANW
$265B
$42.7M 1.77%
1,248,000
+624,000
+100% +$20.8M
ABBV icon
14
AbbVie
ABBV
$455B
$41.4M 1.72%
447,000
– –
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$122B
$41.3M 1.71%
243,000
– –
INST
16
DELISTED
Instructure, Inc.
INST
$40.1M 1.66%
942,000
– –
LOXO
17
DELISTED
Loxo Oncology, Inc
LOXO
$39.7M 1.65%
229,000
– –
LRCX icon
18
Lam Research
LRCX
$372B
$39.2M 1.63%
2,270,000
– –
WCN
19
Waste Connections
WCN
$41.9B
$38.9M 1.62%
517,000
– –
VRNS icon
20
Varonis Systems
VRNS
$4.58B
$38M 1.58%
1,528,584
+91,584
+6% +$2.2M
XIFR
21
XPLR Infrastructure LP
XIFR
$1.12B
$37.6M 1.56%
806,000
+3,800
+0.5% +$162K
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
$37M 1.53%
557,000
– –
MYOV
23
DELISTED
Myovant Sciences Ltd.
MYOV
$36.6M 1.52%
1,601,661
+1,028,108
+179% +$22.5M
STKL
24
DELISTED
SunOpta
STKL
$36.1M 1.5%
4,300,540
– –
MGA icon
25
Magna International
MGA
$19B
$35.7M 1.48%
614,500
-4,000
-0.6% -$248K
1
2 3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2018 Portfolio in Review

As of Q2 2018, Eventide Asset Management held 158 positions worth $2.41B, up 13% from $2.14B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Eventide Asset Management deployed $112M of net new capital in Q2 2018, opening 13 new positions and adding to 40 existing holdings. Its largest new stake was Dianthus Therapeutics: 139,881 shares worth $29.5M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Snap-on, an estimated $10.6M trimmed.

  • Eventide Asset Management's largest Q2 2018 buy was Dianthus Therapeutics: 139,881 shares worth $29.5M.
  • Eventide Asset Management added most to Myovant Sciences Ltd. in Q2 2018, an estimated $22.5M increase.
  • Eventide Asset Management's biggest Q2 2018 reduction was Snap-on, cutting an estimated $10.6M.
  • Eventide Asset Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 25% of its $2.41B portfolio in Q2 2018.
  • Eventide Asset Management opened 13 new positions and closed 14 in Q2 2018.
  • Eventide Asset Management's portfolio value rose 13% quarter-over-quarter to $2.41B.

Based on Eventide Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.